However, vaccination with a mutated form of HSP70i (HSP70iQ435A), developed in our lab, tolerizes DCs, prevents depigmentation and elicits tumor control in mouse models, pointing to a separation of tumor immunity and autoimmune responses, testable in Sinclair swine with melanoma and vitiligo. Here, HSPA1A is linked to vitiligo.